AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 242 min read$BEAT

HeartBeam, Inc. (BEAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001779372 0001779372 2026-06-18 2026-06-18 0001779372 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001779372 us-gaap:WarrantMember 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

Original reporting
SEC EDGAR 8-K
Published Jun 24, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$BEAT
Neutral
medium confidence
Mentioned
$BEAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BEATNeutralMed
01

Why it matters

The company will operate under focused implementation teams led by Branislav Vajdic (Founder/President) and Rich Ferrari (Executive Chairman), with Vajdic serving as principal executive officer effective July 1 until a new CEO is identified.

02

Market read

This is a governance/leadership catalyst that can re-rate near-term execution risk, but it lacks financial metrics or guidance changes.

03

What to watch

The 8-K notes severance is contingent on a release and that a consulting/advisory arrangement is expected; investors may need to watch for any related-party or cost implications not quantified here.

Relevance 6/10Novelty 6/10Timing: after-hours/filing update on June 24, 2026 following June 18 executive changes

Background

HeartBeam filed an 8-K (Item 5.02) on June 24, 2026 describing CEO Robert P. Eno’s mutual departure (effective June 30) and board resignation by Mark Strome (effective immediately).

Company-level read

Ticker impact

$BEATNeutralMedium confidence
Context

HeartBeam disclosed CEO Robert P. Eno’s departure effective June 30, 2026 and named Dr. Branislav Vajdic as principal executive officer starting July 1.

Expected impact

Likely choppy trading around governance/execution expectations; direction depends on investor confidence in the interim leadership and any forthcoming CEO search details.

Evidence & confidence

The filing is a primary-source 8-K detailing executive departures/appointments, but it provides no financial guidance or quantified impact, limiting conviction on magnitude/direction.

Market effects

Sector

No direct sector datapoint; however, leadership churn can affect sentiment toward small-cap biotech/health-tech governance risk broadly.

Regional

Primarily US small-cap sentiment; limited spillover expected beyond the issuer.

Global

Low—this is company-specific governance/management news with no cross-border deal/regulatory element.

Counterpoint

What could challenge this read

Founder/president stepping into principal executive officer role could reduce disruption versus an external interim CEO, potentially stabilizing operations.

Key entities

  • issuer
    HeartBeam, Inc.

    Subject of the 8-K; disclosed CEO departure and interim principal executive officer appointment.

  • executive
    Robert P. Eno

    Mutually agreed to depart as CEO, board member, and principal executive officer effective June 30, 2026.

  • executive
    Branislav Vajdic

    Founder and President; expected to serve as principal executive officer effective July 1, 2026.

  • director
    Mark Strome

    Resigned from the board and all committees effective immediately on June 18, 2026.

  • executive
    Rich Ferrari

    Executive Chairman; to lead focused implementation teams alongside Vajdic.

Read at source← All news

Related articles

OCT 6
$BEATMedAI 8/10

Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news

H.C. Wainwright maintained a Neutral rating on Heartbeam Inc. (BEAT) after its HeartBeam System received FDA Breakthrough Device designation. The stock rose 78% to $0.65, with a market cap of $36.86M. The designation, based on ALIGN-ACS study data, expedites Medicare coverage. BEAT reported a Q2 EPS of -$1.10, missing estimates by $1.01, and plans a $25M equity offering.

investing.com2 min
OCT 5
$BEATHighAI 8/10

Why is Heartbeam stock surging today?

HeartBeam's stock rose 56.6% after the FDA granted Breakthrough Device Designation for its HeartBeam System, a tool for evaluating potential heart attacks. The designation was granted in 30 days, ahead of the standard 60-day review period. HeartBeam estimates the heart attack assessment market at $15 billion, with a broader cardiac platform opportunity exceeding $40 billion. The NASDAQ and S&P 500 also saw modest gains.

investing.com1 min
OCT 5
$BEATHighAI 9/10

HeartBeam stock soars on FDA breakthrough designation

HeartBeam Inc (BEAT) shares rose 90% after the FDA granted Breakthrough Device Designation for its at-home heart attack assessment tool. The designation accelerates FDA review and opens expedited Medicare coverage pathways. HeartBeam estimates the heart attack market opportunity at $15 billion. The company plans to seek FDA alignment on a pivotal study design and begin patient enrollment soon.

investing.com2 min
AUG 13
$BEATMed

Why is Heartbeam stock sliding today?

Heartbeam Inc shares fell 1.7% after hours to $0.58 after the company reported Q2 2026 results. Net loss was $0.10 per share versus a $0.09 estimate, with operating expenses of $5.1M. Heartbeam lowered full-year 2026 cash outflow guidance and said ALIGN-ACS pilot enrollment was completed early.

investing.com4 min
OCT 7
$PCVXHighAI 9/10

Vaxcyte prices US$1B stock, warrants and notes

Vaxcyte, Inc. (NASDAQ: PCVX) raised about US$1B through concurrent stock, warrant, and convertible-note offerings. The company plans to use proceeds for clinical trials, manufacturing, and potential U.S. launch of its pneumococcal vaccine VAX-31. Vaxcyte's shares were trading at US$56.48 on Oct. 2, before the offering.

mugglehead.com2 min